{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:39:44Z","timestamp":1792517984775,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32261143731"],"award-info":[{"award-number":["32261143731"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32470937"],"award-info":[{"award-number":["32470937"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.canlet.2026.218563","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:55:34Z","timestamp":1778025334000},"page":"218563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["IL-12 augments adoptive cell therapy by reshaping CD8+ T dynamics and broadening antitumor immunity"],"prefix":"10.1016","volume":"652","author":[{"given":"Yue","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junshi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-6617","authenticated-orcid":false,"given":"Yang-Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaopeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218563_bib1","doi-asserted-by":"crossref","first-page":"280ps7","DOI":"10.1126\/scitranslmed.aaa3643","article-title":"Adoptive cellular therapy: a race to the finish line","volume":"7","author":"June","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218563_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218563_bib3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1126\/science.abq6990","article-title":"The future of engineered immune cell therapies","volume":"378","author":"Irvine","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218563_bib4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40291-024-00749-3","article-title":"Afamitresgene autoleucel: first approval","volume":"28","author":"Keam","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.canlet.2026.218563_bib5","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218563_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218563_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41571-024-00984-x","article-title":"Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach","volume":"22","author":"Lopez de Rodas","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218563_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217616","article-title":"Clinical development of immuno-oncology therapeutics","volume":"617","author":"Wang","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218563_bib9","article-title":"The role of CAR T-Cell therapy in Relapsed\/Refractory adult B-ALL","volume":"22","author":"Othman","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.canlet.2026.218563_bib10","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2024025828","article-title":"T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities","volume":"144","author":"Hu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218563_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","article-title":"Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies","volume":"31","author":"Anderson","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218563_bib12","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","article-title":"Engineered cellular immunotherapies in cancer and beyond","volume":"28","author":"Finck","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218563_bib13","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218563_bib14","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218563_bib15","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1073\/pnas.0307298101","article-title":"IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells","volume":"101","author":"Klebanoff","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218563_bib16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218563_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218563_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-Specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218563_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.952231","article-title":"IL12 immune therapy clinical trial review: novel strategies for avoiding CRS-associated cytokines","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218563_bib20","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218563_bib21","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218563_bib22","doi-asserted-by":"crossref","first-page":"eabi6899","DOI":"10.1126\/sciimmunol.abi6899","article-title":"A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors","volume":"7","author":"Xue","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218563_bib23","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41551-022-00888-0","article-title":"Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker","volume":"6","author":"Mansurov","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.canlet.2026.218563_bib24","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/2326-6066.CIR-22-0705","article-title":"mWTX-330, an IL-12 INDUKINE molecule, activates and reshapes tumor-infiltrating CD8+ T and NK cells to generate antitumor immunity","volume":"11","author":"Nirschl","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218563_bib25","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20241454","article-title":"Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control","volume":"222","author":"Peng","year":"2025","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218563_bib26","doi-asserted-by":"crossref","first-page":"eads1328","DOI":"10.1126\/sciimmunol.ads1328","article-title":"An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses","volume":"10","author":"Aunins","year":"2025","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218563_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.168224","article-title":"Intratumoral aluminum hydroxide-anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment","volume":"8","author":"Battula","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218563_bib28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41551-020-0549-2","article-title":"Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours","volume":"4","author":"Mansurov","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.canlet.2026.218563_bib29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218563_bib30","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8(+) T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218563_bib31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.immuni.2009.11.012","article-title":"Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells","volume":"32","author":"Pipkin","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218563_bib32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1084\/jem.20130901","article-title":"IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo","volume":"211","author":"Starbeck-Miller","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218563_bib33","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218563_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm.4015","article-title":"Prospects for gene-engineered T cell immunotherapy for solid cancers","volume":"22","author":"Klebanoff","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218563_bib35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218563_bib36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1126\/science.aav8692","article-title":"Enhanced CAR\u2013T cell activity against solid tumors by vaccine boosting through the chimeric receptor","volume":"365","author":"Ma","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218563_bib37","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218563_bib38","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with Neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218563_bib39","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional Mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218563_bib40","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218563_bib41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218563_bib42","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1038\/s41467-023-40115-1","article-title":"Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218563_bib43","article-title":"Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery","author":"Murad","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.canlet.2026.218563_bib44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218563_bib45","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218563_bib46","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.celrep.2018.01.072","article-title":"Suppression of Tcf1 by inflammatory cytokines facilitates effector CD8 T cell differentiation","volume":"22","author":"Danilo","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218563_bib47","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218563_bib48","doi-asserted-by":"crossref","first-page":"eabk1900","DOI":"10.1126\/scitranslmed.abk1900","article-title":"TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","author":"Meyran","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218563_bib49","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218563_bib50","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.ymthe.2020.07.018","article-title":"IL-15 preconditioning augments CAR T cell responses to checkpoint blockade for improved treatment of solid tumors","volume":"28","author":"Giuffrida","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218563_bib51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bjc.2012.581","article-title":"Cancer heterogeneity: implications for targeted therapeutics","volume":"108","author":"Fisher","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218563_bib52","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1158\/1078-0432.CCR-20-0305","article-title":"The role of antigen spreading in the efficacy of immunotherapies","volume":"26","author":"Brossart","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218563_bib53","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218563_bib54","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity","volume":"21","author":"Lai","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218563_bib55","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ccell.2019.10.006","article-title":"Intratumor adoptive transfer of IL-12 mRNA transiently engineered Antitumor CD8(+) T cells","volume":"36","author":"Etxeberria","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218563_bib56","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220745","article-title":"An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery","volume":"219","author":"Shen","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218563_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-024-01303-6","article-title":"Concurrent intratumoural T(reg) cell depletion and CD8(+) T cell expansion via a cleavable anti-4-1BB-interleukin-15 fusion protein","author":"Cai","year":"2024","journal-title":"Nat. Biomed. Eng."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526003265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526003265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:00:50Z","timestamp":1792515650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526003265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":57,"alternative-id":["S0304383526003265"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218563","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-12 augments adoptive cell therapy by reshaping CD8+ T dynamics and broadening antitumor immunity","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218563"}}